R&D News | pharmaphorum

News

Apollo, Nimbus lead bumper week for biotech financings

This week saw a series of big-ticket funding rounds for biotech companies, with Apollo Therapeutics and Nimbus Therapeutics both pulling in upwards of $200 million, in a p

News

Seagen partners Nurix on 'degrader-antibody conjugates'

Seagen hasn't let a pending acquisition by Pfizer interrupt its business development activities, adding to its pipeline with a wide-ranging partnership with Nurix Therapeu

News

Lift for Roche as Alnylam drug lowers blood pressure

Just weeks after wagering $310 million upfront on the rights to Alnylam's hypertension therapy zilebesiran on the strength of phase 1 data, Roche has been rewarded by a po

News

Grogan named Biogen research chief as reset continues

Chris Viehbacher's efforts to reinvigorate Biogen are continuing to take shape with the appointment of industry veteran Jane Grogan to the position of head of research.

News

Deal allows UK to rejoin EU's Horizon R&D funding scheme

After years of Brexit-related wrangling, the UK is poised to rejoin the EU's Horizon Europe programme which provides funding for scientific research.

News

Moderna, Pfizer say COVID jabs work against BA.2.86

Moderna and Pfizer have both said that updated versions of their COVID-19 vaccines work against the highly mutated BA.2.86 variant, also known as Pirola, which is being cl

Apollo, Nimbus lead bumper week for biotech financings

Seagen partners Nurix on 'degrader-antibody conjugates'

Lift for Roche as Alnylam drug lowers blood pressure

Grogan named Biogen research chief as reset continues

Deal allows UK to rejoin EU's Horizon R&D funding scheme

Moderna, Pfizer say COVID jabs work against BA.2.86

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks